{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Imlygic&page=2", "query": { "intervention": "Imlygic", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Imlygic&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-24T03:00:56.364Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03886311", "title": "Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma" ], "interventions": [ { "name": "Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC]", "type": "DRUG" }, { "name": "Nivolumab IV Soln 100 MG/10ML", "type": "DRUG" }, { "name": "Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sarcoma Oncology Research Center, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2019-05-15", "completion_date": "2031-07-31", "has_results": false, "last_update_posted_date": "2025-02-24", "last_synced_at": "2026-09-24T03:00:56.364Z", "location_count": 1, "location_summary": "Santa Monica, California", "locations": [ { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03886311" }, { "nct_id": "NCT00289016", "title": "A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Talimogene Laherparepvec", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioVex Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2005-12", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2015-12-18", "last_synced_at": "2026-09-24T03:00:56.364Z", "location_count": 7, "location_summary": "La Jolla, California • Los Angeles, California • Aurora, Colorado + 4 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Robbinsdale", "state": "Minnesota" }, { "city": "Montclair", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00289016" }, { "nct_id": "NCT07102394", "title": "Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "NF1", "Neurofibromatosis", "Cutaneous Neurofibroma", "Neurofibroma", "Von Recklinghausen Disease", "Neurofibromas" ], "interventions": [ { "name": "Imlygic", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2026-02-01", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-09-24T03:00:56.364Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07102394" }, { "nct_id": "NCT02978625", "title": "Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anaplastic Large Cell Lymphoma, ALK-Negative", "Anaplastic Large Cell Lymphoma, ALK-Positive", "Apocrine Carcinoma", "Carcinoma Arising From Cylindroma", "Carcinoma Arising From Spiradenoma", "Digital Papillary Adenocarcinoma", "Endocrine Mucin-Producing Sweat Gland Carcinoma", "Extramammary Paget Disease", "Extraocular Sebaceous Carcinoma", "Hidradenocarcinoma", "Malignant Sweat Gland Neoplasm", "Merkel Cell Carcinoma", "Microcystic Adnexal Carcinoma", "NK-Cell Lymphoma, Unclassifiable", "Papillary Adenocarcinoma", "Porocarcinoma", "Primary Cutaneous Mucinous Carcinoma", "Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Recurrent T-Cell Non-Hodgkin Lymphoma", "Refractory Anaplastic Large Cell Lymphoma", "Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Refractory Merkel Cell Carcinoma", "Refractory Mycosis Fungoides", "Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Refractory Skin Squamous Cell Carcinoma", "Refractory T-Cell Non-Hodgkin Lymphoma", "Sezary Syndrome", "Signet Ring Cell Adenocarcinoma", "Skin Adenoid Cystic Carcinoma", "Skin Adnexal Carcinoma", "Skin Basal Cell Carcinoma", "Skin Basosquamous Cell Carcinoma", "Skin Keratoacanthoma", "Skin Squamous Cell Carcinoma", "Squamoid Eccrine Ductal Carcinoma", "Squamous Cell Carcinoma of Unknown Primary", "Sweat Gland Carcinoma", "Trichilemmal Carcinoma", "Vulvar Squamous Cell Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Mammography", "type": "PROCEDURE" }, { "name": "Talimogene Laherparepvec", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2017-09-27", "completion_date": "2027-09-01", "has_results": false, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-09-24T03:00:56.364Z", "location_count": 36, "location_summary": "Los Angeles, California • Orange, California • Pasadena, California + 28 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02978625" }, { "nct_id": "NCT02453191", "title": "TVEC and Preop Radiation for Sarcoma (4 ml Dose)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Soft Tissue Sarcoma" ], "interventions": [ { "name": "Talimogene Laherparepvec", "type": "DRUG" }, { "name": "Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Iowa", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2015-07-13", "completion_date": "2023-03-10", "has_results": true, "last_update_posted_date": "2024-06-20", "last_synced_at": "2026-09-24T03:00:56.364Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT02453191" }, { "nct_id": "NCT04068181", "title": "Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Talimogene laherparepvec", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 72, "start_date": "2020-01-22", "completion_date": "2024-02-26", "has_results": true, "last_update_posted_date": "2025-01-07", "last_synced_at": "2026-09-24T03:00:56.364Z", "location_count": 10, "location_summary": "Santa Barbara, California • Newark, Delaware • Orlando, Florida + 7 more", "locations": [ { "city": "Santa Barbara", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Orlando", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Fridley", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04068181" }, { "nct_id": "NCT03256344", "title": "Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Triple Negative Breast Cancer", "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Talimogene Laherparepvec", "type": "BIOLOGICAL" }, { "name": "Atezolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 36, "start_date": "2018-03-19", "completion_date": "2021-12-03", "has_results": true, "last_update_posted_date": "2024-05-14", "last_synced_at": "2026-09-24T03:00:56.364Z", "location_count": 3, "location_summary": "Los Angeles, California • New York, New York • Stony Brook, New York", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Stony Brook", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03256344" }, { "nct_id": "NCT02658812", "title": "Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Chest Wall Neoplasm", "Recurrent Breast Carcinoma", "Recurrent Inflammatory Breast Carcinoma", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Inflammatory Breast Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Talimogene Laherparepvec", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2016-08-01", "completion_date": "2021-12-01", "has_results": true, "last_update_posted_date": "2023-01-25", "last_synced_at": "2026-09-24T03:00:56.364Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02658812" }, { "nct_id": "NCT03921073", "title": "Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Angiosarcoma of Skin" ], "interventions": [ { "name": "T-VEC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2019-08-20", "completion_date": "2021-09-28", "has_results": true, "last_update_posted_date": "2022-11-01", "last_synced_at": "2026-09-24T03:00:56.364Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03921073" }, { "nct_id": "NCT03842943", "title": "Neoadjuvant Combination Immunotherapy for Stage III Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous Melanoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Talimogene Laherparepvec", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Louisville", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2019-07-03", "completion_date": "2028-06-01", "has_results": false, "last_update_posted_date": "2024-05-02", "last_synced_at": "2026-09-24T03:00:56.364Z", "location_count": 1, "location_summary": "Louisville, Kentucky", "locations": [ { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT03842943" } ] }